The phosphatase that opposes PI3K–when lost, Akt activation drives cancer progression.
PI3K phosphorylates PIP2 to generate PIP3, which recruits and activates Akt. PTEN performs the reverse reaction, dephosphorylating PIP3 back to PIP2. This creates a balance: PI3K drives pathway activation; PTEN restrains it.
When PTEN is lost, PIP3 accumulates, Akt is constitutively recruited to the membrane and activated. This explains why PTEN loss phenocopies PI3K activation or Akt overexpression.
The Brake Pedal: PTEN removes the phosphate groups that PI3K adds. It's the natural "off switch" for the PI3K/Akt pathway.
When PTEN Works: Growth signals activate PI3K briefly, then PTEN turns things back down. The pathway cycles appropriately.
PTEN is one of the most frequently altered tumor suppressors. Mechanisms of inactivation include:
Mutation: Germline PTEN mutations cause Cowden syndrome with cancer predisposition.
Deletion: Hemizygous or homozygous loss common in prostate, glioblastoma.
Epigenetic silencing: Promoter methylation reduces expression.
PTEN loss correlates with aggressive disease and poor prognosis across cancer types.
Common Event: PTEN loss (by deletion, mutation, or silencing) is one of the most frequent alterations in cancer.
The Result: Without PTEN, PI3K/Akt signaling runs unchecked, promoting cell survival and growth.
PTEN status is typically assessed by IHC (protein loss) or sequencing (mutations). But these don't directly measure pathway output. The Akt activationLoading... FRET studies demonstrated that activation state predicts outcomes where expression doesn't.
PTEN-null tumors should show high Akt activation by FRET. This functional readout integrates PTEN status with all other pathway regulators, providing a more complete picture of pathway dependence.
Indirect Measurement: Since PTEN loss leads to Akt hyperactivation, measuring Akt activation provides a functional readout of PTEN pathway status.
Clinical Value: This captures the functional consequence of PTEN alterations, regardless of the specific mechanism of PTEN inactivation.
Indirect Application: PTEN loss leads to PI3K/Akt pathway hyperactivation–precisely the pathway validated by QF-Pro. The validated aFRET Akt assay can functionally identify PTEN-deficient tumors through elevated Akt activation, complementing genetic PTEN testing.
Indirect application: PTEN loss drives Akt hyperactivation. The validated Akt assay can functionally identify PTEN-deficient tumors, complementing genetic testing.
